The Medical Research Council Myeloma IX Trial: The Impact on Treatment Paradigms

DSpace/Manakin Repository

The Medical Research Council Myeloma IX Trial: The Impact on Treatment Paradigms

Citable link to this page


Title: The Medical Research Council Myeloma IX Trial: The Impact on Treatment Paradigms
Author: Richardson, Paul Gerard Guy; Laubach, Jacob; Schlossman, Robert Lawrence; Ghobrial, Irene; Mitsiades, Constantine S; Rosenblatt, Jacalyn Mara; Mahindra, Anuj; Raje, Noopur; Munshi, Nikhil C; Anderson, Kenneth Carl

Note: Order does not necessarily reflect citation order of authors.

Citation: Richardson, Paul G., Jacob P. Laubach, Robert L. Schlossman, Irene M. Ghobrial, Constantine S. Mitsiades, Jacalyn Rosenblatt, Anuj Mahindra, et al. 2011. The Medical Research Council myeloma IX trial: The impact on treatment paradigms. European Journal of Haematology 88(1): 1-7.
Full Text & Related Files:
Abstract: Osteolytic bone disease is a hallmark of symptomatic multiple myeloma. Bisphosphonates have been the mainstay of treatment to preserve skeletal integrity and prevent skeletal-related events in patients with myeloma-related bone disease. Recently, the MRC Myeloma IX trial demonstrated for the first time improved survival and delayed disease progression with the use of an intravenous amino-bisphosphonate, zoledronic acid, vs. an oral agent, clodronate, with intensive and non-intensive anti-myeloma treatment regimens in patients with newly diagnosed multiple myeloma. These results validate a large body of preclinical, translational and other clinical data suggesting anti-myeloma effects of amino-bisphosphonates. In addition, this trial also provided the first head-to-head evidence for superiority of one bisphosphonate over another (zoledronic acid vs. clodronate) for reducing skeletal morbidity in patients with multiple myeloma, as well as a prospective comparison of toxicities. Despite the use of non-bortezomib containing anti-myeloma treatment regimens in the MRC Myeloma IX trial, these results are encouraging and provide an impetus to continue to evaluate current treatment guidelines for myeloma-associated bone disease.
Published Version: doi:10.1111/j.1600-0609.2011.01721.x
Other Sources:
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at
Citable link to this page:
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search